Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation

Autor: Antoine Hadengue, Hanspeter Egger, Emiliano Giostra, Gilles Mentha, Ronald Fried, Francesco Negro, Pierre-Alain Clavien, Stephan Kraehenbuhl, Gerd A. Kullak-Ublick, Walter Keller, Claire Vanlemmens, Philippe Morel, Sandrine Locher
Rok vydání: 2003
Předmět:
Male
Cirrhosis
Time Factors
medicine.medical_treatment
Hepacivirus
Liver transplantation
ddc:616.07
Liver Transplantation/adverse effects
medicine.disease_cause
Gastroenterology
Severity of Illness Index
chemistry.chemical_compound
Recurrence
Medicine
ddc:616
biology
ddc:617
Hepatitis C
Middle Aged
Viral Load
Treatment Outcome
RNA
Viral
Drug Therapy
Combination
Female
Viral load
Antiviral Agents/administration & dosage
Adult
medicine.medical_specialty
Hepacivirus/genetics/isolation & purification
Hepatitis C/drug therapy/pathology
Hepatitis C
Chronic/prevention & control
Hepatitis C virus
Interferon-alpha/administration & dosage
Antiviral Agents
Drug Administration Schedule
Internal medicine
Ribavirin
Humans
RNA
Viral/blood
Aged
Transplantation
business.industry
Interferon-alpha
Hepatitis C
Chronic
medicine.disease
biology.organism_classification
Liver Transplantation
chemistry
Immunology
business
Ribavirin/administration & dosage
Zdroj: Transplant International, Vol. 17, No 4 (2004) pp. 169-76
ISSN: 0934-0874
Popis: Hepatitis C virus (HCV) infection invariably recurs after liver transplantation (LT), and sequels of chronic hepatitis of the graft are a significant cause of morbidity and mortality. In an uncontrolled trial, 31 patients with histologically confirmed hepatitis C after LT received, sequentially, ribavirin (10 mg/kg body weight q.d.) for 12 weeks, followed by ribavirin at the same dose q.d. plus interferon-alpha (IFN-alpha) [3 million units three times a week (3 MU TIW)] for another 48 weeks. Based on an intent-to-treat analysis, the percentages of patients with undetectable HCV RNA in their serum were 0%, 38.7% and 45.2% after 12, 36 and 60 weeks of therapy, respectively. A sustained virological response, as defined by undetectable serum HCV RNA 24 weeks after the end of treatment, was observed in 9/31 patients (29%). Sustained responders had a significant improvement of their liver inflammatory activity score (P=0.025), but not of their liver fibrosis score. The chances of sustained virological response correlated with the length of treatment, but not with the HCV genotype or baseline HCV RNA level. In conclusion, patients with recurrent hepatitis C after LT might benefit from ribavirin/IFN-alpha therapy, provided that the treatment is tolerated for a sufficient duration of time.
Databáze: OpenAIRE
Externí odkaz: